Jazz Pharmaceuticals Completes Biologics License Application for Zanidatamab for HER2-Positive Metastatic Biliary Tract Cancer

Approval would mark first HER2-targeted therapy for biliary tract cancer in the United States.

Leave a Reply

Your email address will not be published. Required fields are marked *